Curanex Pharmaceuticals (CURX) Registration Filing summary

Company overview and business model

• Focuses on discovering, developing, and commercializing innovative botanical drugs for inflammatory diseases, leveraging a proprietary platform for identifying and optimizing anti-inflammatory compounds from medicinal plants.

• Lead candidate, Phyto-N, is a botanical extract with a history of use in traditional Chinese medicine, targeting multiple indications including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, gout, and acne.

• Business model includes product sales, collaborations, licensing, and research grants, with initial revenue expected post-commercialization of approved drugs.

• Acquired four provisional patent applications and eight preclinical animal studies from a related party, Duraviva Pharma Inc, in exchange for cash and equity.

Financial performance and metrics

• No revenue generated in 2023 or the first half of 2024, following a strategic shift from dietary supplements to pharmaceutical R&D.

• Net loss of $124,401 for the six months ended June 30, 2024, and $19,198 for the year ended December 31, 2023.

• Cash and cash equivalents totaled $374,261 as of June 30, 2024, with total assets of $715,832 and shareholders' equity of $715,231.

• Company remains unprofitable, with negative cash flows from operations and dependence on future equity or debt financing.

Use of proceeds and capital allocation

• Estimated net proceeds of $8 million (or $9.34 million if over-allotment is exercised) based on a $5.00/share IPO price.

• 25.1% allocated to FDA-required GLP toxicology and pharmacokinetic studies for Phyto-N in ulcerative colitis and IND preparation.

• 12.6% for manufacturing clinical trial material; 37.7% for initiating and conducting Phase I clinical trial for Phyto-N in ulcerative colitis.

• 24.7% for working capital and general corporate purposes.

• Full business plan through FDA approval and product launch estimated to require over $150 million, with future phases dependent on additional fundraising.